CN1119336C - 新的具有止痛作用的化合物 - Google Patents

新的具有止痛作用的化合物 Download PDF

Info

Publication number
CN1119336C
CN1119336C CN96180102A CN96180102A CN1119336C CN 1119336 C CN1119336 C CN 1119336C CN 96180102 A CN96180102 A CN 96180102A CN 96180102 A CN96180102 A CN 96180102A CN 1119336 C CN1119336 C CN 1119336C
Authority
CN
China
Prior art keywords
compound
piperazinyl
benzyl
methyl
diethylbenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96180102A
Other languages
English (en)
Chinese (zh)
Other versions
CN1209124A (zh
Inventor
E·罗伯茨
N·普罗贝克
C·瓦勒斯特德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca Canada Inc
Original Assignee
Astra Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Inc filed Critical Astra Pharma Inc
Publication of CN1209124A publication Critical patent/CN1209124A/zh
Application granted granted Critical
Publication of CN1119336C publication Critical patent/CN1119336C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN96180102A 1995-12-22 1996-12-11 新的具有止痛作用的化合物 Expired - Fee Related CN1119336C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9504661-1 1995-12-22
SE95046611 1995-12-22
SE9504661A SE9504661D0 (sv) 1995-12-22 1995-12-22 New compounds

Publications (2)

Publication Number Publication Date
CN1209124A CN1209124A (zh) 1999-02-24
CN1119336C true CN1119336C (zh) 2003-08-27

Family

ID=20400739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96180102A Expired - Fee Related CN1119336C (zh) 1995-12-22 1996-12-11 新的具有止痛作用的化合物

Country Status (27)

Country Link
US (3) US6130222A (enExample)
EP (2) EP1408037A1 (enExample)
JP (1) JP2000502679A (enExample)
KR (2) KR100493832B1 (enExample)
CN (1) CN1119336C (enExample)
AR (2) AR005420A1 (enExample)
AU (1) AU715547B2 (enExample)
BR (1) BR9612204A (enExample)
CA (1) CA2239174C (enExample)
CZ (1) CZ296159B6 (enExample)
EE (1) EE04640B1 (enExample)
EG (1) EG25688A (enExample)
HU (1) HUP9901304A3 (enExample)
IL (1) IL124996A (enExample)
IS (1) IS1839B (enExample)
MY (1) MY115662A (enExample)
NO (1) NO310869B1 (enExample)
NZ (1) NZ324887A (enExample)
PL (1) PL193061B1 (enExample)
RU (2) RU2307833C2 (enExample)
SE (1) SE9504661D0 (enExample)
SK (1) SK282743B6 (enExample)
TR (1) TR199801180T2 (enExample)
TW (1) TW458971B (enExample)
UA (1) UA71538C2 (enExample)
WO (1) WO1997023466A1 (enExample)
ZA (1) ZA9610352B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410537B1 (en) * 1994-09-09 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Compositions having neuroprotective and analgesic activity
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
CA2316341A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
US6436959B1 (en) 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
JP2003518119A (ja) 1999-12-22 2003-06-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ４−［アリール（８−アザビシクロ［３．２．１］オクタン−３−イル）］アミノ安息香酸誘導体
US6552036B2 (en) 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
SE0001208D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
WO2002044159A2 (en) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
US6887876B2 (en) 2000-12-14 2005-05-03 Ortho-Mcneil Pharmaceutical, Inc. Benzamidine derivatives
SE0100764D0 (sv) * 2001-03-07 2001-03-07 Astrazeneca Ab New assymetric process
SE0101766D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101768D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
NZ539828A (en) * 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
SE0101765D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
SE0103313D0 (sv) 2001-10-03 2001-10-03 Astrazeneca Ab Novel compounds
JP4892654B2 (ja) * 2001-10-29 2012-03-07 マウント クック ファーマ，インコーポレーテッド デルタレセプターアゴニスト化合物によるうつ病の治療方法
PL372096A1 (en) 2002-01-02 2005-07-11 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US8476280B2 (en) * 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
WO2004035541A1 (en) * 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
WO2005075472A1 (en) * 2004-02-03 2005-08-18 Janssen Pharmaceutica, N.V. 3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane and 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
KR101234421B1 (ko) * 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0402485D0 (sv) 2004-10-13 2004-10-13 Astrazeneca Ab Polymorph of N,N-Diethyl-4-(3-Fluorophenyl-Piperidin-4-Ylidene-Methyl)-Benzamide Hydrochloride salt
US7598261B2 (en) * 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CN101198330A (zh) * 2005-04-14 2008-06-11 蒙特库克生物科学公司 新阿片类化合物的组合物及其使用方法
JP2008546765A (ja) * 2005-06-20 2008-12-25 アストラゼネカ アクチボラグ （アルコキシカルボニルアミノ）−アルキルスルホネートの製造方法
EA201001644A1 (ru) * 2008-05-20 2011-06-30 Астразенека Аб Способ лечения тревожного большого депрессивного расстройства
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
US20110172425A1 (en) 2008-09-17 2011-07-14 Calyx Chemicals And Pharmaceuticals Pvt. Ltd. Novel water based process for the preparation of substituted diphenylmethyl piperazines
US20100311782A1 (en) * 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585209A5 (enExample) * 1973-06-29 1977-02-28 Cermol Sa
DE2900810A1 (de) * 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) * 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
JPS57149282A (en) * 1981-02-06 1982-09-14 Ucb Sa 2-(4-(diphenylmethyl)-1-piperazinyl)acetic acid and their derivatives as medicine
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) * 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) * 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
RU2093156C1 (ru) 1989-11-22 1997-10-20 Жансен Фармасетика Н.В. L-(-)-2-(аминокарбонил)-n-(4-амино-2,6-дихлорфенил-4[5,5-бис(4-фторфенил)пентил]-1-пиперазинацетамид, его фармацевтически приемлемая кислотно-аддитивная соль или гидрат, способ его получения и средство для хранения сердца донора
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5681830A (en) * 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
FR2696744B1 (fr) * 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
WO1995004051A1 (en) * 1993-07-30 1995-02-09 The Wellcome Foundation Limited Piperazine compounds used in therapy
JP3352184B2 (ja) * 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
SE9504662D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
CA2316341A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
SE0001209D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds

Also Published As

Publication number Publication date
PL327403A1 (en) 1998-12-07
RU2194702C2 (ru) 2002-12-20
CA2239174C (en) 2007-09-04
IL124996A0 (en) 1999-01-26
US6680321B1 (en) 2004-01-20
AR005420A1 (es) 1999-06-23
IL124996A (en) 2007-07-04
CZ296159B6 (cs) 2006-01-11
CA2239174A1 (en) 1997-07-03
AU1216297A (en) 1997-07-17
SE9504661D0 (sv) 1995-12-22
US6130222A (en) 2000-10-10
SK82298A3 (en) 1998-11-04
BR9612204A (pt) 1999-07-13
IS4769A (is) 1998-06-11
MX9804798A (es) 1998-10-31
CN1209124A (zh) 1999-02-24
TR199801180T2 (xx) 1998-10-21
EP1408037A1 (en) 2004-04-14
UA71538C2 (en) 2004-12-15
AU715547B2 (en) 2000-02-03
TW458971B (en) 2001-10-11
CZ176898A3 (cs) 1998-09-16
NO982807D0 (no) 1998-06-18
EP0915855A1 (en) 1999-05-19
EE04640B1 (et) 2006-06-15
PL193061B1 (pl) 2007-01-31
NO982807L (no) 1998-08-19
SK282743B6 (sk) 2002-11-06
AR034116A2 (es) 2004-02-04
RU2307833C2 (ru) 2007-10-10
MY115662A (en) 2003-08-30
ZA9610352B (en) 1997-06-23
KR100493832B1 (ko) 2005-09-26
NZ324887A (en) 2000-01-28
EE9800194A (et) 1998-12-15
US20040138228A1 (en) 2004-07-15
EG25688A (en) 2012-05-20
IS1839B (is) 2002-12-18
NO310869B1 (no) 2001-09-10
HUP9901304A3 (en) 2003-04-28
JP2000502679A (ja) 2000-03-07
KR19990076648A (ko) 1999-10-15
HUP9901304A2 (hu) 1999-08-30
WO1997023466A1 (en) 1997-07-03
KR20050047534A (ko) 2005-05-20

Similar Documents

Publication Publication Date Title
CN1209124A (zh) 新的具有止痛作用的化合物
CN1114596C (zh) 联苯基衍生物
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1146540C (zh) 具有镇痛作用的新化合物及其用途
CN1326440A (zh) 哌啶ccr－3受体拮抗剂
CN1444573A (zh) 甲酰胺化合物及其作为人11cby受体拮抗剂的用途
CN1113236A (zh) 非肽基速激肽受体拮抗剂
CN1522249A (zh) 作为神经肽y受体的配体的喹啉衍生物
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN1039996C (zh) N－取代氮杂双环庚烷衍生物及其用途
CN1105853A (zh) 抑制骨损失的方法
CN101044115A (zh) 治疗阿尔茨海默病的哌啶及相关化合物
CN1890208A (zh) 类鸦片受体拮抗剂
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1050604C (zh) 具有抗精神病作用的化合物
CN1031262C (zh) 环取代的2-氨基-1，2，3，4-四氢化萘和3-氨基苯并二氢吡喃
CN1293663A (zh) 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸
CN1225465C (zh) 新化合物
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1711252A (zh) 4－(苯基－哌嗪基－甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途
CN1993338A (zh) 二芳基甲基哌嗪衍生物及其制备方法和用途
CN1711251A (zh) 4－(苯基－哌嗪基－甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途
HK1045684B (zh) 联苯基衍生物
CN101039927A (zh) 5－羟色胺5－ht3受体激动剂
CN1193014C (zh) 新的吡咯磺酰胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030827

Termination date: 20111211